A Combination of Microarray-Based Profiling and Biocomputational Analysis Identified miR331-3p and hsa-let-7d-5p as Potential Biomarkers of Ulcerative Colitis Progression to Colorectal Cancer.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 May 2024
Historique:
received: 22 03 2024
revised: 06 05 2024
accepted: 15 05 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

Ulcerative colitis (UC), an inflammatory bowel disease (IBD), may increase the risk of colorectal cancer (CRC) by activating chronic proinflammatory pathways. The goal of this study was to find serum prediction biomarkers in UC to CRC development by combining low-density miRNA microarray and biocomputational approaches. The UC and CRC miRNA expression profiles were compared by low-density miRNA microarray, finding five upregulated miRNAs specific to UC progression to CRC (hsa-let-7d-5p, hsa-miR-16-5p, hsa-miR-145-5p, hsa-miR-223-5p, and hsa-miR-331-3p). The circRNA/miRNA/mRNA competitive endogenous RNA (ceRNA) network analysis showed that the candidate miRNAs were connected to well-known colitis-associated CRC ACVR2A, SOCS1, IGF2BP1, FAM126A, and CCDC85C mRNAs, and circ-SHPRH circRNA. SST and SCARA5 genes regulated by hsa-let-7d-5p, hsa-miR-145-5p, and hsa-miR-331-3p were linked to a poor survival prognosis in a CRC patient dataset from The Cancer Genome Atlas (TCGA). Lastly, our mRNA and miRNA candidates were validated by comparing their expression to differentially expressed mRNAs and miRNAs from colitis-associated CRC tissue databases. A high level of hsa-miR-331-3p and a parallel reduction in SOCS1 mRNA were found in tissue and serum. We propose hsa-miR-331-3p and possibly hsa-let-7d-5p as novel serum biomarkers for predicting UC progression to CRC. More clinical sample analysis is required for further validation.

Identifiants

pubmed: 38891888
pii: ijms25115699
doi: 10.3390/ijms25115699
pii:
doi:

Substances chimiques

MicroRNAs 0
mirnlet7 microRNA, human 0
Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : EPInhibitDRUGre
ID : B66J20000680005;

Auteurs

Pilar Chacon-Millan (P)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Stefania Lama (S)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Nunzio Del Gaudio (N)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Antonietta Gerarda Gravina (AG)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Alessandro Federico (A)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Raffaele Pellegrino (R)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Amalia Luce (A)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Lucia Altucci (L)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Biogem Scarl, Institute of Genetic Research, Laboratory of Molecular and Precision Oncology, 83031 Ariano Irpino, Italy.
Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore" (IEOS)-National Research Council (CNR), Via Sergio Pansini, 80131 Naples, Italy.
Programma di Epigenetica Medica, A.O.U. "Luigi Vanvitelli", 80138 Naples, Italy.

Angelo Facchiano (A)

Institute of Food Sciences, National Research Council, 83100 Avellino, Italy.

Michele Caraglia (M)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Biogem Scarl, Institute of Genetic Research, Laboratory of Molecular and Precision Oncology, 83031 Ariano Irpino, Italy.
Programma di Epigenetica Medica, A.O.U. "Luigi Vanvitelli", 80138 Naples, Italy.

Paola Stiuso (P)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH